Should I Buy Alcoa Stock?
Alcoa (AA) finds itself in an interesting position in early…
Sell
33
PBE Quote, Financials, Valuation and Earnings
Last price:
$61.89
Seasonality move
:
3.59%
Day range:
$61.89 - $63.44
52-week range:
$59.32 - $72.84
Dividend yield:
0.07%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
9.4K
Avg. volume:
7.6K
1-year change:
-3.62%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- |
|
BBH
VanEck Biotech ETF
|
-- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
PSCH
Invesco S&P SmallCap Health Care ETF
|
-- | -- | -- | -- | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
$62.09 | -- | -- | -- | $0.03 | 0.07% | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
$16.53 | -- | -- | -- | $0.24 | 1.45% | -- |
|
BBH
VanEck Biotech ETF
|
$153.99 | -- | -- | -- | $1.25 | 0.81% | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
$83.88 | -- | -- | -- | $0.27 | 1.08% | -- |
|
PSCH
Invesco S&P SmallCap Health Care ETF
|
$42.24 | -- | -- | -- | $0.01 | 0.23% | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
$81.76 | -- | -- | -- | $0.03 | 0.04% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 1.213 | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | 1.341 | -- | -- |
|
BBH
VanEck Biotech ETF
|
-- | 1.074 | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | 0.655 | -- | -- |
|
PSCH
Invesco S&P SmallCap Health Care ETF
|
-- | 1.638 | -- | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
-- | 1.595 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- | -- |
|
BBH
VanEck Biotech ETF
|
-- | -- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
PSCH
Invesco S&P SmallCap Health Care ETF
|
-- | -- | -- | -- | -- | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- | -- |
Invesco Biotechnology & Genome ETF vs. Competitors
-
Which has Higher Returns PBE or BBC?
Virtus LifeSci Biotech Clinical Trials ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat Virtus LifeSci Biotech Clinical Trials ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -
What do Analysts Say About PBE or BBC?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Clinical Trials ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than Virtus LifeSci Biotech Clinical Trials ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than Virtus LifeSci Biotech Clinical Trials ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 -
Is PBE or BBC More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.883, which suggesting that the stock is 11.713% less volatile than S&P 500. In comparison Virtus LifeSci Biotech Clinical Trials ETF has a beta of 1.134, suggesting its more volatile than the S&P 500 by 13.44%.
-
Which is a Better Dividend Stock PBE or BBC?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.07%. Virtus LifeSci Biotech Clinical Trials ETF offers a yield of 1.45% to investors and pays a quarterly dividend of $0.24 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Clinical Trials ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or BBC?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than Virtus LifeSci Biotech Clinical Trials ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Clinical Trials ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for Virtus LifeSci Biotech Clinical Trials ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- --
-
Which has Higher Returns PBE or BBH?
VanEck Biotech ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat VanEck Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- BBHVanEck Biotech ETF-- -- -- -
What do Analysts Say About PBE or BBH?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand VanEck Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than VanEck Biotech ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than VanEck Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 BBHVanEck Biotech ETF0 0 0 -
Is PBE or BBH More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.883, which suggesting that the stock is 11.713% less volatile than S&P 500. In comparison VanEck Biotech ETF has a beta of 0.860, suggesting its less volatile than the S&P 500 by 14.037%.
-
Which is a Better Dividend Stock PBE or BBH?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.07%. VanEck Biotech ETF offers a yield of 0.81% to investors and pays a quarterly dividend of $1.25 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. VanEck Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or BBH?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than VanEck Biotech ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than VanEck Biotech ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while VanEck Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for VanEck Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- BBHVanEck Biotech ETF-- -- -- --
-
Which has Higher Returns PBE or PJP?
Invesco Pharmaceuticals ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat Invesco Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- -
What do Analysts Say About PBE or PJP?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than Invesco Pharmaceuticals ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than Invesco Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 PJPInvesco Pharmaceuticals ETF0 0 0 -
Is PBE or PJP More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.883, which suggesting that the stock is 11.713% less volatile than S&P 500. In comparison Invesco Pharmaceuticals ETF has a beta of 0.585, suggesting its less volatile than the S&P 500 by 41.535%.
-
Which is a Better Dividend Stock PBE or PJP?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.07%. Invesco Pharmaceuticals ETF offers a yield of 1.08% to investors and pays a quarterly dividend of $0.27 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. Invesco Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or PJP?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than Invesco Pharmaceuticals ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than Invesco Pharmaceuticals ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while Invesco Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for Invesco Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns PBE or PSCH?
Invesco S&P SmallCap Health Care ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat Invesco S&P SmallCap Health Care ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- PSCHInvesco S&P SmallCap Health Care ETF-- -- -- -
What do Analysts Say About PBE or PSCH?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco S&P SmallCap Health Care ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than Invesco S&P SmallCap Health Care ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than Invesco S&P SmallCap Health Care ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 PSCHInvesco S&P SmallCap Health Care ETF0 0 0 -
Is PBE or PSCH More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.883, which suggesting that the stock is 11.713% less volatile than S&P 500. In comparison Invesco S&P SmallCap Health Care ETF has a beta of 1.009, suggesting its more volatile than the S&P 500 by 0.85900000000001%.
-
Which is a Better Dividend Stock PBE or PSCH?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.07%. Invesco S&P SmallCap Health Care ETF offers a yield of 0.23% to investors and pays a quarterly dividend of $0.01 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. Invesco S&P SmallCap Health Care ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or PSCH?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than Invesco S&P SmallCap Health Care ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than Invesco S&P SmallCap Health Care ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while Invesco S&P SmallCap Health Care ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for Invesco S&P SmallCap Health Care ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- PSCHInvesco S&P SmallCap Health Care ETF-- -- -- --
-
Which has Higher Returns PBE or XHE?
SPDR S&P Health Care Equipment ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat SPDR S&P Health Care Equipment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- XHESPDR S&P Health Care Equipment ETF-- -- -- -
What do Analysts Say About PBE or XHE?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Health Care Equipment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than SPDR S&P Health Care Equipment ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than SPDR S&P Health Care Equipment ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 XHESPDR S&P Health Care Equipment ETF0 0 0 -
Is PBE or XHE More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.883, which suggesting that the stock is 11.713% less volatile than S&P 500. In comparison SPDR S&P Health Care Equipment ETF has a beta of 1.111, suggesting its more volatile than the S&P 500 by 11.072%.
-
Which is a Better Dividend Stock PBE or XHE?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.07%. SPDR S&P Health Care Equipment ETF offers a yield of 0.04% to investors and pays a quarterly dividend of $0.03 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. SPDR S&P Health Care Equipment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or XHE?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than SPDR S&P Health Care Equipment ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than SPDR S&P Health Care Equipment ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while SPDR S&P Health Care Equipment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for SPDR S&P Health Care Equipment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- XHESPDR S&P Health Care Equipment ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Nu Holdings Stock Be in 2030?
Despite fast growth, high profitability and an extraordinary runway ahead,…
Is it Too Late to Buy United Airlines Stock?
United Airlines (NASDAQ:UAL) has thoroughly outpaced the broader stock market…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
GATE alert for Apr 2
Marblegate Acquisition [GATE] is up 86.64% over the past day.
Buy
52
NUTX alert for Apr 2
Nutex Health [NUTX] is up 5.41% over the past day.
Buy
75
CORT alert for Apr 2
Corcept Therapeutics [CORT] is down 8.84% over the past day.
